TR200100708T2 - İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler. - Google Patents

İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler.

Info

Publication number
TR200100708T2
TR200100708T2 TR2001/00708T TR200100708T TR200100708T2 TR 200100708 T2 TR200100708 T2 TR 200100708T2 TR 2001/00708 T TR2001/00708 T TR 2001/00708T TR 200100708 T TR200100708 T TR 200100708T TR 200100708 T2 TR200100708 T2 TR 200100708T2
Authority
TR
Turkey
Prior art keywords
composition
powder
active substance
release pharmaceutical
sieve
Prior art date
Application number
TR2001/00708T
Other languages
English (en)
Turkish (tr)
Inventor
Bertelsen Poul
Gjerlov Hansen Nils
Ruckendorfer Hermann
Itai Shigeru
Original Assignee
Nycomed Danmark A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Danmark A/S filed Critical Nycomed Danmark A/S
Publication of TR200100708T2 publication Critical patent/TR200100708T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2001/00708T 1998-09-10 1999-09-10 İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler. TR200100708T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA199801143 1998-09-10

Publications (1)

Publication Number Publication Date
TR200100708T2 true TR200100708T2 (tr) 2001-07-23

Family

ID=8101500

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00708T TR200100708T2 (tr) 1998-09-10 1999-09-10 İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler.

Country Status (13)

Country Link
US (1) US6713089B1 (enExample)
EP (1) EP1109534B1 (enExample)
JP (2) JP5026635B2 (enExample)
AT (1) ATE232382T1 (enExample)
AU (1) AU5504599A (enExample)
CA (1) CA2343148C (enExample)
DE (1) DE69905380T2 (enExample)
DK (1) DK1109534T3 (enExample)
EA (1) EA004032B1 (enExample)
ES (1) ES2190241T3 (enExample)
PT (1) PT1109534E (enExample)
TR (1) TR200100708T2 (enExample)
WO (1) WO2000015195A1 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US20030161875A1 (en) * 2002-02-27 2003-08-28 Deepak Murpani Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
JP2009513512A (ja) * 2003-07-09 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2572359C (en) * 2004-06-29 2010-08-03 Nycomed Danmark Aps Manufacturing of quick release pharmaceutical compositions of water insoluble drugs and pharmaceutical compositions obtained by the process of the invention
JP5490347B2 (ja) * 2005-05-27 2014-05-14 エスエス製薬株式会社 経口投与用製剤
JO3352B1 (ar) 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
WO2007010559A2 (en) 2005-07-20 2007-01-25 Panacea Biotec Ltd. Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
WO2007078874A2 (en) * 2005-12-30 2007-07-12 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
EP2019586A4 (en) * 2006-05-03 2009-09-02 Proethic Pharmaceuticals Inc MEDICATION OF ACUTE PAIN BASED ON FAST DICLOFENAC OPIOID COMBINATIONS
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
WO2008062449A2 (en) * 2006-09-18 2008-05-29 Glenmark Pharmaceuticals Limited A novel pharmaceutical soft gel composition containing dexibuprofen and paracetamol
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
RS53245B2 (sr) * 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
US8821924B2 (en) 2007-09-14 2014-09-02 Wockhardt Ltd. Rhein or diacerein compositions
NZ587202A (en) 2008-01-04 2013-03-28 Schabar Res Associates Llc Methods for measuring a patient response upon administration of a drug and compositions thereof
BRPI0912326A2 (pt) 2008-05-20 2015-10-06 Neurogesx Inc análogos de acetaminofeno hidrossolúveis
CA2724881C (en) 2008-05-20 2016-09-27 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
PL2432472T3 (pl) 2009-05-22 2020-03-31 Incyte Holdings Corporation 3-[4-(7H-Pirolo[2,3-d]pirymidyn-4-ylo)-1H-pirazol-1-ilo]oktano- lub heptano-nitryle jako inhibitory JAK
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PL2488145T3 (pl) 2009-10-12 2024-08-26 Boehringer Ingelheim Vetmedica Gmbh Pojemniki na kompozycje zawierające meloksykam
WO2011107150A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
MX354212B (es) 2010-03-10 2018-02-19 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
EP2394641A1 (en) 2010-05-30 2011-12-14 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of lornoxicam
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012146314A1 (en) 2011-04-29 2012-11-01 Refarmed Chemicals Sa Thin gelatin capsules for rapid drug release in the mouth
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP2012012411A (ja) * 2011-10-03 2012-01-19 Ssp Co Ltd 経口投与用製剤
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
ES2699806T3 (es) 2012-04-18 2019-02-12 SpecGx LLC Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US20130310435A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
NZ708157A (en) 2012-11-15 2019-07-26 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
TWI634121B (zh) 2013-03-06 2018-09-01 英塞特控股公司 用於製備ｊａｋ抑制劑之方法及中間物
WO2014152296A1 (en) 2013-03-15 2014-09-25 Mallinckrodt Llc Abuse deterrent solid dosage form for immediate release with functional score
JP2013216701A (ja) * 2013-07-29 2013-10-24 Ssp Co Ltd 経口投与用製剤
KR101890649B1 (ko) * 2013-07-30 2018-09-28 라이온 가부시키가이샤 정제
MX394928B (es) 2013-08-07 2025-03-24 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP3164117B1 (en) 2014-07-03 2023-09-06 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
WO2017048720A1 (en) 2015-09-15 2017-03-23 Praxis Biosciences, Llc Prodrugs of fencamfamine
WO2018197932A1 (en) 2017-04-27 2018-11-01 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of ketorolac
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
WO2019152374A1 (en) 2018-01-30 2019-08-08 Incyte Corporation Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
HUE067471T2 (hu) 2018-03-30 2024-10-28 Incyte Corp Gennyes verejtékmirigy-gyulladás kezelése jak inhibitorok alkalmazásával
JP7170437B2 (ja) * 2018-06-29 2022-11-14 小林製薬株式会社 内服用医薬組成物
EP3856160A4 (en) 2018-09-25 2022-07-06 SpecGx LLC ANTI-ABUSE IMMEDIATE RELEASE CAPSULES DOSAGE FORMS
US11779541B2 (en) * 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form
CA3160312A1 (en) 2019-11-22 2021-05-27 Incyte Corporation Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
JP7499025B2 (ja) * 2019-12-27 2024-06-13 小林製薬株式会社 内服用医薬組成物
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
IL299845A (en) 2020-07-15 2023-03-01 Schabar Res Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965072A (en) * 1988-11-03 1990-10-23 Miles Inc. Granulating composition and method
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
JP2906528B2 (ja) * 1990-02-14 1999-06-21 大正製薬株式会社 吸収を促進した内服用固形製剤
CA2061520C (en) * 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
BR9507768A (pt) * 1994-05-27 1997-09-02 Farmarc Nederland Bv Composição farmacêutica
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition

Also Published As

Publication number Publication date
US6713089B1 (en) 2004-03-30
JP5622703B2 (ja) 2014-11-12
EA200100331A1 (ru) 2001-08-27
AU5504599A (en) 2000-04-03
EA004032B1 (ru) 2003-12-25
DK1109534T3 (da) 2003-06-10
PT1109534E (pt) 2003-06-30
ES2190241T3 (es) 2003-07-16
JP2012082197A (ja) 2012-04-26
JP2002524492A (ja) 2002-08-06
EP1109534B1 (en) 2003-02-12
JP5026635B2 (ja) 2012-09-12
CA2343148C (en) 2005-11-15
CA2343148A1 (en) 2000-03-23
WO2000015195A1 (en) 2000-03-23
DE69905380T2 (de) 2003-11-27
ATE232382T1 (de) 2003-02-15
DE69905380D1 (de) 2003-03-20
EP1109534A1 (en) 2001-06-27

Similar Documents

Publication Publication Date Title
TR200100708T2 (tr) İlaç maddelerine mahsus çabuk salımlı farmasötik bileşimler.
DK1441704T3 (da) Orodispersibel tablet med höj homogenitet og fremgangsmåde til fremstilling heraf
DE69934135D1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
SK5672001A3 (en) Improved fast disintegrating tablet
EA200601588A1 (ru) Стабилизированные перенасыщенные твёрдые растворы липофильных лекарственных средств
ES2543427T3 (es) Forma farmacéutica oral de deferasirox
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
ATE164060T1 (de) Inhalationspulver und verfahren zu ihrer herstellung
BG105379A (en) Pharmaceutical compositions for the treatment of acute disorders
IT9022155A0 (it) Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione
DE60113809D1 (de) Pharmazeutische kombination aus mikronisiertem drospirenon und einen estrogen für die hormonersatztherapie
RU2006142322A (ru) Фармацевтические композиции
KR960021061A (ko) 경구 투여용 약제학적 조성물
EE200000186A (et) Osake, selliste osakeste valmistamismeetod ja kasutamine, farmatseutiline doosivorm ja selle valmistamismeetod, tahke dispersioon ja farmatseutiline pakend
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
Zimm et al. Drug release from a multiparticulate pellet system
DK1267833T3 (da) Farmaceutiske præparater og fremgangsmåde til fremstilling deraf
DE69408122D1 (de) Zusammensetzung aus mikropartikeln in verdichteter phase und verfahren
CY1113221T1 (el) Διεργασια για την παρασκευη ενος φαρμακου
Cook et al. Factors modifying susceptibility to bacterial endotoxin: the effect of lead and cadmium
Guo et al. Investigation of the release of aspirin from spray-congealed micro-pellets
ES2193562T3 (es) Dispositivo de dosificacion.
JP2789115B2 (ja) 可溶性コラーゲンパウダーを担体とする粒状医薬徐放剤の製造方法
NO20011670L (no) Preparat for parenteral administrering av aktive forbindelser